Literature DB >> 1704903

Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils.

E Roilides1, T J Walsh, P A Pizzo, M Rubin.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) stimulates proliferation of myeloid cells and may be a valuable adjunct in prevention and treatment of neutropenia-associated infections. Neutrophil (PMNL) phagocytic and microbicidal functions against Staphylococcus aureus and Candida albicans blastoconidia were therefore evaluated. Bacterial phagocytosis and bactericidal activity were significantly enhanced by approximately 50%-70% after preincubation of normal PMNL with G-CSF in concentrations of 1000-4000 units/ml for 10 min at 37 degrees C. G-CSF in similar concentrations enhanced the defective bactericidal activity of PMNL from HIV-1-infected patients by approximately 70%-150% and reached the baseline control PMNL killing. However, G-CSF enhanced neither phagocytosis nor fungicidal activity of normal PMNL against C. albicans blastoconidia. These data demonstrate that G-CSF enhances the antibacterial but not the antifungal activities of human PMNL in vitro and also improves the defective PMNL bactericidal activity of HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704903     DOI: 10.1093/infdis/163.3.579

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  68 in total

1.  Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.

Authors:  Yoshihiro Yakushijin; Hisaharu Shikata; Ikue Takaoka; Tamami Horikawa; Kazuhito Takeuchi; Jun Yamanouchi; Taichi Azuma; Hiroshi Narumi; Takaaki Hato; Masaki Yasukawa
Journal:  Int J Clin Oncol       Date:  2010-10-06       Impact factor: 3.402

2.  Adjunctive Therapies for Sepsis and Septic Shock.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Colony-Stimulating Factors in the Therapeutic Approach to Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 4.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

5.  Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils.

Authors:  M J Coffey; S M Phare; S George; M Peters-Golden; P H Kazanjian
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

6.  Suppression of polymorphonuclear leukocyte bactericidal activity by suramin.

Authors:  E Roilides; P Paschalides; A Freifeld; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  Enhancement of in vitro bactericidal activity of neutrophils from trauma patients in the presence of granulocyte colony-stimulating factor.

Authors:  K Anding; A Kropec; E Schmidt-Eisenlohr; A Benzing; K Geiger; F Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

9.  Association between elevated plasma granulocyte colony-stimulating factor and the degree of surgical stress in patients undergoing gastrointestinal surgery.

Authors:  K Yokota; T Nishihira; R Shineha; J Sayama; Y Nitta; M Kimura; S Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus.

Authors:  E Roilides; A Dimitriadou-Georgiadou; T Sein; I Kadiltsoglou; T J Walsh
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.